文献速递乳腺癌

曲妥珠单抗美坦新联合阿替利珠单抗对比安慰剂治疗经治HER2阳性晚期乳腺癌的2期随机双盲试验(KATE2)

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

KATE2是一项在9个国家68个中心开展的随机双盲安慰剂对照2期研究,纳入202例既往接受曲妥珠单抗和紫杉烷治疗的HER2阳性晚期乳腺癌患者,按2:1随机分配至曲妥珠单抗美坦新联合阿替利珠单抗组(n=133)或联合安慰剂组(n=69)。

要点

  • 联合组3级及以上不良事件更常见,包括血小板减少和肝酶升高。
  • 研究者建议在PD-L1阳性HER2阳性晚期乳腺癌亚组中进一步研究。

核心结论

  • 在曲妥珠单抗美坦新基础上联合阿替利珠单抗未显示具有临床意义的无进展生存期改善,且不良事件增加。
  • 在PD-L1阳性、HER2阳性晚期乳腺癌亚组中进一步研究曲妥珠单抗美坦新联合阿替利珠单抗是合理的。

研究设计与样本

  • KATE2是一项随机、双盲、安慰剂对照的2期研究,在亚洲、澳大利亚、北美和西欧9个国家的68个中心开展。
  • 随机化按PD-L1状态、世界区域和肝转移分层,主要终点为意向治疗人群的研究者评估无进展生存期。

主要发现

  • 3级及以上不良事件中最常见的是血小板减少(阿替利珠单抗组132例中17例[13%] vs 安慰剂组68例中3例[4%])、天冬氨酸氨基转移酶升高(11例[8%] vs 2例[3%])、贫血(7例[5%] vs 0例)、中性粒细胞减少(6例[5%] vs 3例[4%])和丙氨酸氨基转移酶升高(6例[5%] vs 2例[3%])。
  • 严重不良事件发生在阿替利珠单抗组132例中的43例(33%)和安慰剂组68例中的13例(19%)。
  • 阿替利珠单抗组有1例患者因治疗相关不良事件(噬血细胞综合征)死亡。

临床怎么用

  • 不推荐在未经选择的HER2阳性晚期乳腺癌患者中常规联合曲妥珠单抗美坦新和阿替利珠单抗。
  • 对于PD-L1阳性HER2阳性晚期乳腺癌患者,可考虑在临床试验背景下进一步探索该联合方案。

局限性

  • 研究因无效性和不良事件频率较高而提前揭盲,主要分析基于较短随访时间。
  • 样本量较小(202例),且为2期研究,统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity of trastuzumab emtansine. We aimed to test this combination in HER2-positive advanced breast cancer that had progressed after previous treatment with trastuzumab and a taxane. METHODS: The KATE2 study is a randomised, double-blind, placebo-controlled, phase 2 study at 68 centres from nine countries across Asia, Australia, North America, and western Europe. Eligible patients were adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and centrally confirmed, measurable, HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. Patients were randomly assigned (2:1) either trastuzumab emtansine (3·6 mg/kg of bodyweight) plus atezolizumab (1200 mg) or trastuzumab emtansine plus placebo; all study drugs were administered by intravenous infusion every 3 weeks. Randomisation was done via an interactive voice and web response system using a permuted block scheme (block size of six) and was stratified by PD-L1 status, world region, and liver metastases. Patients, investigators, and study team members were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02924883, and the study has been completed. FINDINGS: Between Sept 26, 2016, and Aug 7, 2017, 330 patients were screened for the study, of whom 202 were randomly allocated either atezolizumab (n=133) or placebo (n=69). At the recommendation of the independent data monitoring committee, treatment assignment was unmasked on Dec 11, 2017, due to futility and the numerically higher frequency of adverse events among patients assigned atezolizumab. This date was set as the clinical cutoff for the primary analysis. Median follow-up was 8·5 months (IQR 6·1-11·5) for patients assigned atezolizumab and 8·4 months (5·3-11·1) for those assigned placebo. Median progression-free survival was 8·2 months (95% CI 5·8-10·7) for patients assigned atezolizumab versus 6·8 months (4·0-11·1) for those assigned placebo (stratified hazard ratio 0·82, 95% CI 0·55-1·23; p=0·33). The most common grade 3 or worse adverse events were thrombocytopenia (17 [13%] among 132 patients who received atezolizumab vs three [4%] among 68 who received placebo), increased aspartate aminotransferase (11 [8%] vs two [3%]), anaemia (seven [5%] vs 0), neutropenia (six [5%] vs three [4%]), and increased alanine aminotransferase (six [5%] vs two [3%]). Serious adverse events occurred in 43 (33%) of 132 patients who received atezolizumab and 13 (19%) of 68 patients who received placebo. One patient who received atezolizumab died due to a treatment-related adverse event (haemophagocytic syndrome). INTERPRETATION: Addition of atezolizumab to trastuzumab emtansine did not show a clinically meaningful improvement in progression-free survival and was associated with more adverse events. Further study of trastuzumab emtansine plus atezolizumab is warranted in a subpopulation of patients with PD-L1-positive, HER2-positive advanced breast cancer. FUNDING: F Hoffman-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020. PMID: 33002436. doi:10.1016/S1470-2045(20)30465-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。